CORD BLOOD BANKING

Cryogene SAL was the first company to promote cord blood stem cell banking in the Middle East. Since 2004, it has been the sole agent for “Smart Cells Ltd” UK leader in cord blood banking.

ONCOLOGY TESTING

Cryogene expanded its activity to Oncology testing, bringing cutting edge specialized tests to the Middle East market, through its cooperation with major laboratories, like Agendia, Natera, Pathgroup and Omicure.

PRENATAL TESTING

Cryogene SAL has been exclusively distributing “Natera Inc” prenatal diagnostic tests, as part of its continuous vision of pursuing excellence in selecting the most advanced tests to serve its patients.

ADVANCED TECHNOLOGY

SEE MORE

CryoGene is commited to bringing cutting edge technology tests to Lebanon and the region.

PROFFESIONAL STAFF

SEE MORE

Our team consist of highly specialized and experienced individuals.

SPECIALIZED LABORATORIES

SEE MORE

Our Laboratories are set with the highest standars and equipment.

WORLDWIDE COLLABORATION

SEE MORE

CryoGene works with various laboratories worldwide.

OUR EXPERIENCED STAFF

Cryogene's team of scientists is fully dedicated to bringing to physicians, laboratories and clinics, the most advanced technology available in the world. We help improve medical services and minimize unnecessary medical acts and complications as well as reduce the national healthcare bill on the long run. Our large panel of internationally approved and accredited tests covers a wide variety of specialties in Oncology, Urology, Pediatrics, Gynecology, Cardiology and many others.

team member thumb
Dr. Gilbert Karayakoupoglou
Regional Operation Manager
team member thumb
Nicole Tannous
Office Manager
team member thumb
Nicolas Allam
Regulatory Affairs
team member thumb
Sally Daher
Medical Representative

Not sure what to do?

NEWS & EVENTS

CryoGene in partnership with Assurex launches CryoCare
February 7, 2019

CryoGene is partnering up with Assurex insurance to give your loved ones a full protection program when you choose Smart Cells to store your baby's stem cells. CryoCare is a financial support for customers who have stored their baby's stem cells at SCI to cover up to 150000$ of stem cells treatment cost. For further details about CryoCare, please contact us!

Read More
Smart Cells releases 1st sample to treat autism
April 11, 2018

Private cord blood company, Smart Cells, has released their 20th sample of stem cells collected from cord blood and tissue to a patient to treat autism. This is the company's first sample to be released and infused for the condition. This release closely coincides with World Autism Awareness Day on the 2nd April, for which Smart Cells have released a simple informational guide on autism for parents.

Read More
Agendia Collaborates with Prestigious Cancer Center, Institut Curie, for MammaPrint® BluePrint® Breast Cancer Kit Co-Validation Study
December 5, 2017

Institut Curie is one of an increasing number of major European cancer centers to become a co-validation partner for the new NGS-based MammaPrint BluePrint Kit.

Read More
New Data at the San Antonio Breast Cancer Symposium Demonstrate the Value of MammaPrint® and BluePrint®Across Breast Cancer Patient Populations
November 30, 2017

IRVINE, CA, AMSTERDAM, NETHERLANDS - 30 November 2017 - Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces the presentation of extensive new data at the upcoming 2017 San Antonio Breast Cancer Symposium (SABCS), highlighting the value of its MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence Test and BluePrint® Breast Cancer Molecular Subtyping Test. A total of eleven posters and discussions are being presented at SABCS, which will take place at the Henry B. Gonzales Convention Center in San Antonio, Texas from December 5-9, 2017.

Read More
NEW STUDY PUBLISHED IN JAMA ONCOLOGY SHOWS MAMMAPRINT® CHANGED BREAST CANCER TREATMENT DECISIONS IN 3 OUT OF 4 CASES WHERE GUIDANCE WAS UNCLEAR WITH THE 21-GENE ASSAY
October 20, 2017

Prospective PROMIS trial showed no correlation between the two tests highlighting potential under-and over-treatment risks throughout the 21-gene assay's intermediate range.
Physicians changed their treatment decisions in approximately 34% of all cases and in 76% of cases where treatment decisions were discordant based on the indication of the MammaPrint test, with 79% of physicians having greater confidence in their recommendation with the added clarity of MammaPrint when the 21-gene assay yielded an intermediate result.
Findings reinforce the recent ASCO Breast Cancer Guideline update which recommends the exclusive use of MammaPrint in clinically high risk and lymph node positive (1-3) patients.

Read More
AGENDIA'S MAMMAPRINT® RECOMMENDED BY ASCO BREAST CANCER GUIDELINE IN FOCUSED UPDATE BASED ON LANDMARK MINDACT TRIAL DATA
July 10, 2017

ASCO® recommends MammaPrint® for clinical high risk, hormone receptor-positive, HER2-negative breast cancer, to inform decisions on withholding chemotherapy. ASCO recommends MammaPrint as currently the only genomic test to be used to guide treatment decisions for 1-3 lymph node positive early-stage breast cancer patients and marks the fourth positive international guideline update for MammaPrint in 2017, recognizing the highest level of clinical evidence provided by MINDACT.

Read More